{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T07:22:08Z","timestamp":1780557728867,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,14]]},"DOI":"10.7759\/cureus.73687","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T14:43:28Z","timestamp":1731595408000},"source":"Crossref","is-referenced-by-count":3,"title":["Exploring the Therapeutic Potential of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in Polycystic Ovary Syndrome"],"prefix":"10.7759","author":[{"given":"Miis","family":"Akel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Ziq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kaldas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jad","family":"Hamden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Rahman","family":"Omari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Silanee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4103\/jhrs.JHRS_95_18","article-title":"The prevalence of polycystic ovary syndrome: a brief systematic review","volume":"13","author":"Deswal R","year":"2020","unstructured":"Deswal R, Narwal V, Dang A, Pundir CS. The prevalence of polycystic ovary syndrome: a brief systematic review. J Hum Reprod Sci. 2020, 13:261-71. 10.4103\/jhrs.JHRS_95_18","journal-title":"J Hum Reprod Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23084334","article-title":"The role of Glp-1 receptor agonists in insulin resistance with concomitant obesity treatment in polycystic ovary syndrome","volume":"23","author":"Bednarz K","year":"2022","unstructured":"Bednarz K, Kowalczyk K, Cwynar M, et al.. The role of Glp-1 receptor agonists in insulin resistance with concomitant obesity treatment in polycystic ovary syndrome. Int J Mol Sci. 2022, 23:4334. 10.3390\/ijms23084334","journal-title":"Int J Mol Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab408","article-title":"Exenatide, dapagliflozin, or phentermine\/topiramate differentially affect metabolic profiles in polycystic ovary syndrome","volume":"106","author":"Elkind-Hirsch KE","year":"2021","unstructured":"Elkind-Hirsch KE, Chappell N, Seidemann E, Storment J, Bellanger D. Exenatide, dapagliflozin, or phentermine\/topiramate differentially affect metabolic profiles in polycystic ovary syndrome. J Clin Endocrinol Metab. 2021, 106:3019-33. 10.1210\/clinem\/dgab408","journal-title":"J Clin Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-015-0161-3","article-title":"Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study","volume":"8","author":"Jensterle M","year":"2015","unstructured":"Jensterle M, Salamun V, Kocjan T, Vrtacnik Bokal E, Janez A. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. J Ovarian Res. 2015, 8:32. 10.1186\/s13048-015-0161-3","journal-title":"J Ovarian Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-017-0155-9","article-title":"Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial","volume":"17","author":"Jensterle M","year":"2017","unstructured":"Jensterle M, Kravos NA, Gori\u010dar K, Janez A. Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. BMC Endocr Disord. 2017, 17:5. 10.1186\/s12902-017-0155-9","journal-title":"BMC Endocr Disord"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0797","article-title":"Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin","volume":"170","author":"Jensterle Sever M","year":"2014","unstructured":"Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA, Janez A. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol. 2014, 170:451-9. 10.1530\/EJE-13-0797","journal-title":"Eur J Endocrinol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa692","article-title":"Exenatide, metformin, or both for prediabetes in PCOS: a randomized, open-label, parallel-group controlled study","volume":"106","author":"Tao T","year":"2021","unstructured":"Tao T, Zhang Y, Zhu YC, et al.. Exenatide, metformin, or both for prediabetes in PCOS: a randomized, open-label, parallel-group controlled study. J Clin Endocrinol Metab. 2021, 106:e1420-32. 10.1210\/clinem\/dgaa692","journal-title":"J Clin Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3109\/07435800.2014.966385","article-title":"Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome","volume":"40","author":"Jensterle M","year":"2015","unstructured":"Jensterle M, Kocjan T, Kravos NA, Pfeifer M, Janez A. Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome. Endocr Res. 2015, 40:133-8. 10.3109\/07435800.2014.966385","journal-title":"Endocr Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-015-0005-6","article-title":"The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls","volume":"15","author":"Kahal H","year":"2015","unstructured":"Kahal H, Aburima A, Ungvari T, et al.. The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls. BMC Endocr Disord. 2015, 15:14. 10.1186\/s12902-015-0005-6","journal-title":"BMC Endocr Disord"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2017.03.023","article-title":"Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial","volume":"35","author":"Nylander M","year":"2017","unstructured":"Nylander M, Fr\u00f8ssing S, Clausen HV, Kistorp C, Faber J, Skouby SO. Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reprod Biomed Online. 2017, 35:121-7. 10.1016\/j.rbmo.2017.03.023","journal-title":"Reprod Biomed Online"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13454","article-title":"Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight\/obese polycystic ovary syndrome","volume":"87","author":"Liu X","year":"2017","unstructured":"Liu X, Zhang Y, Zheng SY, et al.. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight\/obese polycystic ovary syndrome. Clin Endocrinol (Oxf). 2017, 87:767-74. 10.1111\/cen.13454","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/BF03401383","article-title":"A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome","volume":"14","author":"Jensterle M","year":"2015","unstructured":"Jensterle M, Kravos NA, Pfeifer M, Kocjan T, Janez A. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. Hormones (Athens). 2015, 14:81-90. 10.1007\/BF03401383","journal-title":"Hormones (Athens)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14944","article-title":"Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity","volume":"25","author":"Jensterle M","year":"2023","unstructured":"Jensterle M, Ferjan S, Le\u017eai\u010d L, So\u010dan A, Gori\u010dar K, Zaletel K, Janez A. Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity. Diabetes Obes Metab. 2023, 25:975-84. 10.1111\/dom.14944","journal-title":"Diabetes Obes Metab"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12185915","article-title":"Do GLP-1 analogs have a place in the treatment of PCOS? New insights and promising therapies","volume":"12","author":"Szczesnowicz A","year":"2023","unstructured":"Szczesnowicz A, Szeliga A, Niwczyk O, Bala G, Meczekalski B. Do GLP-1 analogs have a place in the treatment of PCOS? New insights and promising therapies. J Clin Med. 2023, 12:5915. 10.3390\/jcm12185915","journal-title":"J Clin Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.124","article-title":"The effect of the GLP-1 analogue Exenatide on functional connectivity within an NTS-based network in women with and without obesity","volume":"3","author":"Coveleskie K","year":"2017","unstructured":"Coveleskie K, Kilpatrick LA, Gupta A, et al.. The effect of the GLP-1 analogue Exenatide on functional connectivity within an NTS-based network in women with and without obesity. Obes Sci Pract. 2017, 3:434-45. 10.1002\/osp4.124","journal-title":"Obes Sci Pract"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/biolre\/ioad032","article-title":"Glucagon-like peptide-1 receptor agonists decrease hyperinsulinemia and hyperandrogenemia in dehydroepiandrosterone-induced polycystic ovary syndrome mice and are associated with mitigating inflammation and inducing browning of white adipose tissue\u2020","volume":"108","author":"Zhang Y","year":"2023","unstructured":"Zhang Y, Lin Y, Li G, et al.. Glucagon-like peptide-1 receptor agonists decrease hyperinsulinemia and hyperandrogenemia in dehydroepiandrosterone-induced polycystic ovary syndrome mice and are associated with mitigating inflammation and inducing browning of white adipose tissue\u2020. Biol Reprod. 2023, 108:945-59. 10.1093\/biolre\/ioad032","journal-title":"Biol Reprod"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01034-w","article-title":"Once-daily oral semaglutide versus injectable GLP-1 RAs in people with type 2 diabetes inadequately controlled on basal insulin: systematic review and network meta-analysis","volume":"12","author":"Chubb B","year":"2021","unstructured":"Chubb B, Gupta P, Gupta J, Nuhoho S, Kallenbach K, Orme M. Once-daily oral semaglutide versus injectable GLP-1 RAs in people with type 2 diabetes inadequately controlled on basal insulin: systematic review and network meta-analysis. Diabetes Ther. 2021, 12:1325-39. 10.1007\/s13300-021-01034-w","journal-title":"Diabetes Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/151695","article-title":"GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: current research and future horizons","volume":"31","author":"Papaetis GS","year":"2022","unstructured":"Papaetis GS, Kyriacou A. GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: current research and future horizons. Adv Clin Exp Med. 2022, 31:1265-74. 10.17219\/acem\/151695","journal-title":"Adv Clin Exp Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10081989","article-title":"Therapeutic potential of glucagon-like peptide-1 agonists in polycystic ovary syndrome: from current clinical evidence to future perspectives","volume":"10","author":"Jensterle M","year":"2022","unstructured":"Jensterle M, Herman R, Jane\u017e A. Therapeutic potential of glucagon-like peptide-1 agonists in polycystic ovary syndrome: from current clinical evidence to future perspectives. Biomedicines. 2022, 10:1989. 10.3390\/biomedicines10081989","journal-title":"Biomedicines"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/247821-exploring-the-therapeutic-potential-of-glucagon-like-peptide-1-glp-1-receptor-agonists-in-polycystic-ovary-syndrome","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T14:43:29Z","timestamp":1731595409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/247821-exploring-the-therapeutic-potential-of-glucagon-like-peptide-1-glp-1-receptor-agonists-in-polycystic-ovary-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.73687","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,14]]}}}